reference

Jenke D. Strategic aspects of change control. European Pharmaceutical Review. 2017;22(2):60-62

Posted: 12 July 2017 | | No comments yet

References

  1. Arbin A, Jacobsson S, Hanninen K, Hagman A, Ostelius J. Studies on the contamination of intravenous solutions from PVC-bags with dynamic headspace GC-MS and LC-diode array techniques. Int J Pharm. 1986;28(2-3):211-218.
  2. Goydan R, Schwope AD, Redi RC, Cramer G. High-temperature migration of anti-oxidants from polyolefins. Food Additives and Contaminants. 1990;7(3):323-337.
  3. Kim-Kang H, Gilbert SG. Isolation and identification of potential migrants in gamma-irradiated and non-irradiated plastic laminates for unit dose injection device. Appl Spectrosc. 1991;45(4):572-580.
  4. Sarbach C, Yagoubi N, Sauzieres J, Renaux C, Ferrier D, Postaire E. Migration of impurities from a multi-layer plastic container into a parenteral infusion solution. Int J Pharm. 1996;140:169-174.
  5. Kim H, Gilbert SG, Johnson JB. Determination of potential migrants from commercial amber polyethylene terephthalate bottle wall. Pharm Res. 1990;7(2):176-179.
  6. Danielson DM, Oxborrow GS, Placencia AM. Chemical leaching of rubber stoppers into parenteral solutions. J Parent Sci Technol. 1983;37(3):89-92.
  7. Reif AW, Solkner P, Rupp J. Analysis and evaluation of filter cartridge extractables for validation in pharmaceutical downstream processing. PDA J Pharm Sci Technol. 1996;50(6):399-410
  8. Jenke D R. Extractable/leachable substances from plastic materials used as pharmaceutical product containers/devices. PDA J Pharm Sci Technol. 2002;56(6):332-371.
  9. Guidance for Industry. Container Closure Systems for Packaging Human Drugs and Biologics. U.S. Department of Health and Human Services, Food and Drug Administration; Rockville, MD. May1999.
  10. Guideline on Plastic Immediate Packaging Materials. European Medicines Agency. CPMP/QWWP/4359/03. EMEA/CVMP/205/04. 5/19/05.
  11. Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. PQRI Leachables and Extractables Working Group. September 9, 2006. Available at http://www.pqri.org/pdfs/LE-Recommendations-to-FDA-09-29-06.pdf.
  12. Guidance for Industry. M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. U.S. Department of Health and Human Services, Food and Drug Administration; Rockville, MD. May 2015.
  13. 〈661.1〉 PLASTIC MATERIALS OF CONSTRUCTION. USP39-NF34, page 493. Official May 1, 2016.
  14. 3.1.6. Polypropylene for Containers and Closures for Parenteral Preparations and Ophthalmic Preparations. European Pharmacopoeia 8.0. Council of Europe, Strasbourg, 2014, pp. 388.

Send this to a friend